Bladder cancer patients with stable or progressive disease (SD/PD, n = 230) exhibited a significantly higher PTGS2 gene expression when compared to patients demonstrating complete or partial response (CR/PR, n = 68) (p = 0.03, Fig. 7e). Here, PTGS2 is linked to urinary bladder carcinoma.